With the city hall scandals in Toronto and Montreal, Canada is looking more like its southern neighbor than ever
United and Delta will measure the passenger's financial value to the airline instead of the miles she's logged
The good news? People tend to moderate the extremity of their views on complicated issues after they've tried to explain how they actually work
A debate between Ribbit Capital's Micky Malka and Tangent Capital's Jim Rickards changed audience members' minds about the virtual currency
A new report finds debt relief firms charge for help debtors can get for free
Nascar just inked a multiyear agreement with Hewlett-Packard to spearhead innovations in the sport
A classic game comes just in time
Business students may think their choice of major makes them career-saavy, but PayScale says they're the most underemployed college graduates of all
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."